Thyroid safety in patients treated with liraglutide
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
During the last years, various novel anti-diabetic drugs have considerably enriched the therapeutic armamentarium for subjects with Type 2 diabetes. In the meantime, much interest has recently been focused on the potential cardiovascular and oncological adverse effects of these new therapies. As to glucagon-like peptide 1 (GLP-1) analogs, medullary thyroid tumors were reported to be more common in rodent toxicology studies with liraglutide, although the relevance of this finding in humans has been questioned. Analyses of sequential changes in calcitonin levels in several thousands of subjects did not reveal a relationship between liraglutide therapy and plasma calcitonin. Furthermore, no medullary thyroid cancer has been detected in humans taking liraglutide. Nevertheless, the long-term consequences of sustained GLP-1 receptor activation in the human thyroid remain unknown and deserve further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a result, GLP-1 RAs are contraindicated for patients with a personal or family history of MTC or those with multiple endocrine neoplasia syndrome type 2.8,17,22”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [17]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Inzucchi, S., Bergenstal, R., Buse, J., Diamant, M., Ferrannini, E., Nauck, M., Peters, A., Tsapas, A., Wender, R., & Matthews, D. (2013) · Diabetes Care · doi:10.2337/dc13-er02 · Cited by 805
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 5×
“Data from these studies substantiated the following sequence of events, after long-term GLP-1R agonist exposition in rodents: 1) GLP-1R agonists bind to and activate GLP-1R on C-cells; 2) GLP-1R activation on C-cells induces calcitonin (Ct) release; 3) continued Ct release is followed by increased Ct synthesis by the…”
BackgroundInfluentialDiamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · cited 1×
“With regard to the once weekly formulation of exenatide, human studies conducted so far seem equally reassuring: Ct concentrations were within normal limits in all evaluated patients, in a recent open-label randomized trial (43).”
Cummins, E., Royle, P., Snaith, A., Greene, A., Robertson, L., McIntyre, L., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14110 · Cited by 335
Prospects of Remission in Medullary Thyroid Carcinoma According to Basal Calcitonin Level
Machens, A., Schneyer, U., Holzhausen, H.-J., & Dralle, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1836 · Cited by 290
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene
Hoff, A. O., Catala-Lehnen, P., Thomas, P. M., Priemel, M., Rueger, J. M., Nasonkin, I., Bradley, A., Hughes, M. R., Ordonez, N., Cote, G. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200214218 · Cited by 209 · cited 1×
“1%), produce Ct, a 32-amino-acid peptide hormone whose secretion is closely linked to calcium homeostasis in fishes and rodents, in which it seems to inhibit osteoclast-mediated bone resorption (18).”
BackgroundHegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
Waugh, N., Cummins, E., Royle, P., Clar, C., Marien, M., Richter, B., & Philip, S. (2010) · Health Technology Assessment · doi:10.3310/hta14360 · Cited by 176
Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161 · cited 2×
“GLP-1R agonists effects were not found to be mediated by MAPKinase pathway phosphorylation and by activating mutations in the RET proto-oncogene, at least on rodent Ccells (32).”
BackgroundGlucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
Update multiple endocrine neoplasia type 2
Raue, F., & Frank‐Raue, K. (2010) · Familial Cancer · doi:10.1007/s10689-010-9320-2 · Cited by 148
Sex-Related C Cell Hyperplasia in the Normal Human Thyroid: A Quantitative Autopsy Study
Guyetant, S. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.1.42 · Cited by 147
Monami, M., Marchionni, N., & Mannucci, E. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0101 · Cited by 146
d'Herbomez, M., Caron, P., Bauters, C., Do Cao, C., Schlienger, J.-L., Sapin, R., Baldet, L., Carnaille, B., Wémeau, J.-L., & _, _. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0566 · Cited by 134
Monami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C. M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2011) · International Journal of Experimental Diabetes Research · doi:10.1155/2011/215764 · Cited by 125
LiVolsi, V. A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3707 · Cited by 118
Routine serum calcitonin measurement in the evaluation of thyroid nodules
Elisei, R. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.008 · Cited by 98
Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80
Familial medullary thyroid carcinoma and C cell hyperplasia
Wolfe, H. J., & DeLellis, R. A. (1981) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(81)80027-8 · Cited by 74
Is Calcitonin an Important Physiological Substance?
Hirsch, P. F., & Baruch, H. (2003) · Endocrine · doi:10.1385/endo:21:3:201 · Cited by 73
Sosa, J. A., & Udelsman, R. (2006) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2006.05.010 · Cited by 63
O’Toole, K., Fenoglio‐Preiser, C. M., & Pushparaj, N. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80276-8 · Cited by 62
Davies, M. J., Chubb, B., Smith, I., & Valentine, W. J. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03429.x · Cited by 55
Vitale, G., Ciccarelli, A., Caraglia, M., Galderisi, M., Rossi, R., Prete, S. D., Abbruzzese, A., & Lupoli, G. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.9.1505 · Cited by 47
McGill, J. B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.1998 · Cited by 43
Medullary thyroid cancer: an update of new guidelines and recent developments
Wu, L. S., Roman, S. A., & Sosa, J. A. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328340b527 · Cited by 36
Liraglutide for the treatment of type 2 diabetes
Shyangdan, D., Cummins, E., Royle, P., & Waugh, N. (2011) · Health Technology Assessment · doi:10.3310/hta15suppl1-09 · Cited by 34
Ceriello, A., Gallo, M., Armentano, V., Perriello, G., Gentile, S., & Micheli, O. B. O. T. A. A. D. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0233 · Cited by 31
Self-citationRole of calcitonin in the rapid minute‐to‐minute regulation of plasma Ca2+ homeostasis in the rat
Wang, W., Lewin, E., & Ølgaard, K. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.01054.x · Cited by 28
Epigenetics and Diabetes Risk: Not Just for Imprinting Anymore?
Pollin, T. I. (2011) · Diabetes · doi:10.2337/db11-0515 · Cited by 19
Experimental induction of C cell tumours in thyroid by increased dietary content of vitamin D3
Thurston, V., & Williams, E. D. (1982) · European Journal of Endocrinology · doi:10.1530/acta.0.1000041 · Cited by 18
Lee, W. C., Conner, C., & Hammer, M. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.559444 · Cited by 16
Cholecystokinins but not gastrin-17 release calcitonin from thyroid C-cells in the rat
Persson, P., Grunditz, T., Axelson, J., Sundler, F., & Håkanson, R. (1988) · Regulatory Peptides · doi:10.1016/0167-0115(88)90090-0 · Cited by 15
Omeprazole: short- and long-term safety.
Yeomans, N. D. (1994) · PubMed · Cited by 11
Secretion of calcitonin from the thyroid gland increases in aged rats
Kurosawa, M., Sato, A., Shiraki, M., & Takahashi, Y. (1988) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(88)90006-4 · Cited by 8
Diabetes medications and cancer: A way out of uncertainty
Gallo, M., Esposito, K., & Giugliano, D. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.04.007 · Cited by 4
Self-citation
Cited by
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Son, J. W., & Kim, S. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0258 · Cited by 134
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Self-citationA Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
García-Carro, C., Vergara, A., Bermejo, S., Azancot, M. A., Sellarés, J., & Soler, M. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655871 · Cited by 101
Metadata
- Authors
- Gallo, M.
- Affiliations
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Corresponding author
- Gallo, M.
- ORCID
- Gallo, M.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2013-02
- Volume
- 36
- Issue
- 2
- Pages
- 140-145
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2086006571
- Cited by
- 27
- References
- 45
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 7 · 2022: 1 · 2021: 4 · 2020: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2014: 1 · 2013: 1
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- liraglutide, medullary thyroid carcinoma, GLP-1 receptor agonists, type 2 diabetes, calcitonin, drug safety
- MeSH terms
- Liraglutide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Thyroid Gland, Thyroid Neoplasms, Randomized Controlled Trials as Topic, Treatment Outcome, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.